Safety and efficacy of immunotherapy according to the age threshold of 80 years - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Bulletin du Cancer Year : 2023

Safety and efficacy of immunotherapy according to the age threshold of 80 years

Abstract

Background: To compare safety and efficacy of ICIs among patients<80 and those ≥80 years of age. Methods: A single-center retrospective observational cohort study comparing patients<80 and ≥80 years of age matched for cancer site (lung vs others) and participation in a clinical trial. Primary endpoint: grade ≥2 toxicity during the first three months of ICI therapy. The two groups were compared using univariate and multivariate regression. Results: Two hundred and ten consecutive patients were recruited, with the following characteristics: mean age: 66.5±16.8, 20% aged ≥80 years, 75% male, 97% ECOG-PS ≤ 2, 78% G8-index ≤ 14/17, 80% lung or kidney cancer, and 97% metastatic cancer. The grade ≥2 toxicity rate during the first three months of ICI therapy was 68%. Patients aged ≥80 years of age had a more significant (P<0.05) proportion of grade ≥2 non-hematological toxicities (64% vs 45%) than those aged<80 years: rash (14% vs 4%), arthralgia (7.1% vs 0.6%), colitis (4.7% vs 0.6%), cytolysis (7.1% vs 1.2%), gastrointestinal bleeding (2.4% vs 0%), onycholysis (2.4% vs 0%), oral mucositis (2.4% vs 0%), psoriasis (2.4% vs 0%), or other skin toxicities (25% vs 3%). Efficacy among patients ≥80 and<80 years of age was comparable. Conclusions: Although non-hematological toxicities affected 20% more patients aged ≥80 years, hematological toxicities and efficacy were comparable between patients aged ≥80 and<80 years with advanced cancer and treated with ICIs.
Fichier principal
Vignette du fichier
Paillaud_Safety.pdf (480.72 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04150313 , version 1 (04-07-2023)

Identifiers

Cite

Soraya Mebarki, Frédéric Pamoukdjian, Monica Pierro, Johanne Poisson, Capucine Baldini, et al.. Safety and efficacy of immunotherapy according to the age threshold of 80 years. Bulletin du Cancer, 2023, 110 (5), pp.570-580. ⟨10.1016/j.bulcan.2023.02.010⟩. ⟨hal-04150313⟩
32 View
9 Download

Altmetric

Share

Gmail Facebook X LinkedIn More